Company Aggregate Debt: beyondspringpharma.com (BYSI)

BeyondSpring Inc. (BYSI) is developing treatments for chemotherapy-induced neutropenia, aiming to surpass current standards of care. Amid intense pressure from pharma behemoths and patent wars, the amount of funds raised on the GURU.Markets chart demonstrates the debt load, where the 0.00 level serves as a critical solvency benchmark. Meanwhile, the company adheres to ESG principles, strictly controlling the disposal of hazardous chemicals and the ethics of its testing.

This indicator aggregates all creditor obligations and loans, allowing for an assessment of the business's dependence on external capital and the potential pressure on future cash flow. By analyzing the current debt volume, an investor can compare the borrowing rates of BeyondSpring Inc. (BYSI) with the costs of clinical trials and the preparation of drugs for regulatory approval, which is critical for the company's survival.